 |
|
|
| |
Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant
fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week
international, randomized, double blind, placebo-controlled trial
in patients with F2 or F3 fibrosis
|
| |
| |
EASL 2024 June 5-8 Milan Italy
Rohit Loomba
San Diego UCSD USA
|
| |
|
|
|
|
|
